Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· Phase 3· Centre Hospital Region Metz Thionville· Source
Recruiting
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757· Phase 2· Puma Biotechnology, Inc.· Source
Not yet recruiting
Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis
NCT07812701· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
NCT07569536· Phase 3· Hospices Civils de Lyon· Source
Not yet recruiting
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
2025-522819-42-01· Phase 4· Centre Hospitalier Universitaire De Rennes· Source
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
PALETTE - Trial for personalisation of sepsis treatment in children and adults
2025-521371-31-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Recruiting
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source
Recruiting
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma
2024-519208-29-00· Phase 2· Intergroupe Francophone De Cancerologie Thoracique· Source
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· Phase 4· Sanofi· Source
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· Phase 2· AstraZeneca· Source
Recruiting
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"
2023-505781-28-00· Phase 2· French Innovative Leukemia Organization· Source
Not yet recruiting
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2025-521090-14-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Recruiting
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822· Phase 3· AstraZeneca· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial shockable rhythm._PARACA
2023-510099-30-00· Phase 3· Centre Hospitalier De Versailles· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· UNICANCER· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Recruiting
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549· Phase 4· University Hospital, Strasbourg, France· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Not yet recruiting
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
NCT06263816· Phase 3· University Hospital, Tours· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Recruiting
MODULO
NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640· Phase 1· Bayer· Source
Recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· Phase 2· UNICANCER· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Not yet recruiting
Stop Treatment in gout
2024-515714-40-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725· Phase 2· Groupe Oncologie Radiotherapie Tete et Cou· Source
Recruiting
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
NCT06528431· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Lessening Organ Dysfunction with VITamin C in septic ARDS
NCT04404387· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06180382· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· Phase 2· Abivax S.A.· Source
Not yet recruiting
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
NCT06045858· Phase 3· University Hospital, Caen· Source
Recruiting
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· Phase 3· OSE Immunotherapeutics· Source
Showing 50 of 100.